Applied DNA Sciences Faces Nasdaq Delisting Hearing

Applied DNA Sciences ( (APDN) ) has issued an announcement.

Applied DNA Sciences, Inc. received a notification from Nasdaq on May 30, 2025, indicating that the company no longer meets the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. In response, the company implemented a 1-for-15 reverse stock split on June 2, 2025, to regain compliance. Despite this action, the company is not eligible for a compliance period due to previous reverse stock splits and has requested a hearing to prevent delisting. The outcome of the hearing is uncertain, and there is no assurance that the company will maintain its Nasdaq listing.

The most recent analyst rating on (APDN) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Applied DNA Sciences stock, see the APDN Stock Forecast page.

Spark’s Take on APDN Stock

According to Spark, TipRanks’ AI Analyst, APDN is a Neutral.

Applied DNA Sciences faces substantial financial and operational challenges, as indicated by declining revenues and net losses. Despite some positive strategic moves, such as focusing on LineaRx, the stock suffers from poor technical indicators and valuation metrics. The company’s ongoing financial struggles and the uncertainties highlighted in the earnings call contribute to a low overall stock score.

To see Spark’s full report on APDN stock, click here.

More about Applied DNA Sciences

Average Trading Volume: 120,927

Technical Sentiment Signal: Strong Sell

Current Market Cap: $2.86M

For an in-depth examination of APDN stock, go to TipRanks’ Stock Analysis page.